Amgen vs. NovoCure: Which Health Care Stock Is a Better Buy in 2026?
Key PointsAmgen delivers robust cash flow and high net margins through its established portfolio of blockbuster medications...
Nasdaq News: Markets
More News
Amgen Inc. (AMGN) is Attracting Investor Attention: Here is What You Should Know
Amgen (AMGN) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Zacks
J&J Stock Down 3% in 3 Months: Is the Dip a Buying Opportunity?
J&J's shares fall 3% in three months despite solid results and pipeline progress, raising questions about whether the pullback is a buying opportunity.
Zacks
Amgen (AMGN) Sees a More Significant Dip Than Broader Market: Some Facts to Know
The latest trading day saw Amgen (AMGN) settling at $341.66, representing a -1.78% change from its previous close.
Zacks
Why Amgen (AMGN) is a Top Momentum Stock for the Long-Term
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Zacks
Is Amgen Inc. (AMGN) A Good Stock To Buy Now?
Is Amgen Inc. (AMGN) A Good Stock To Buy Now...
Yahoo! Finance: News
Amgen (AMGN) Registers a Bigger Fall Than the Market: Important Facts to Note
In the closing of the recent trading day, Amgen (AMGN) stood at $337.5, denoting a -2.05% move from the preceding trading day.
Zacks
Inside the GLP-1 Boom: ETF Picks for the Obesity Drug Market
GLP-1 drugs are reshaping healthcare and consumer markets. These ETFs offer targeted exposure to the booming obesity-drug trend.
Zacks
Can Amgen's MariTide Win Share in the Fast-Growing Obesity Market?
MariTide's less frequent dosing could help AMGN carve out a place in the rapidly expanding obesity drug market.
Zacks
Sanofi Wins EU Nod for Subcutaneous Sarclisa in Multiple Myeloma
SNY wins EU approval for a subcutaneous Sarclisa option in multiple myeloma, offering faster administration and flexible delivery methods.